Fadi Fakhouri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fadi Fakhouri has a total of 340 co-authors. Here are the top co-authors by number of shared publications:
Nora Schwotzer
Service de Néphrologie et d'Hypertension, Département de Médecine, Centre Hopstialier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland
7 shared publicationsVéronique Frémeaux-Bacchi
Department of Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
6 shared publications- Véronique Frémeaux-Bacchi
Inflammation, Complement and Cancer Team, Cordeliers Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S1138, Paris, France
6 shared publications François Provôt
Univ. Lille, CHU Lille, Nephrology Department, F-59000, Lille, France
4 shared publicationsMoglie Le Quintrec
Department of nephrology, CHU Montpellier, Montpellier. All in France
4 shared publicationsSébastien Kissling
Lausanne Univ, Serv Nephrol & Hypertens, CHUV, Lausanne, Switzerland
4 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN
Background: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Methods: In VALIANT’s 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan ( n =63) or placebo ( n =61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. Results: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, −67.1% [−74.9 to −56.8]; week 52, −67.2% [−75.8 to −55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (–9.6 to 17.9) (26 weeks of placebo), and −53.9% (−64.5 to −40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were −1.2 mL/min/1.73 m 2 (−5.6 to 3.2) (week 26) and –3.7 mL/min/1.73 m 2 (–8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were –7.9 (–11.7 to –4.2) (week 26) and –4.7 (–9.1 to –0.3) (week 52); week-26-to-52 change was +3.0 (–1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan ( n =118) showed proteinuria reduction (geometric mean [95% CI] −63.0% [−69.9 to −54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [−3.8 to 4.0] mL/min/1.73 m 2 ). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. Conclusions: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
- 13 November 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Open AccessPegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN
Background: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Methods: In VALIANT’s 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan ( n =63) or placebo ( n =61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. Results: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, −67.1% [−74.9 to −56.8]; week 52, −67.2% [−75.8 to −55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (–9.6 to 17.9) (26 weeks of placebo), and −53.9% (−64.5 to −40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were −1.2 mL/min/1.73 m 2 (−5.6 to 3.2) (week 26) and –3.7 mL/min/1.73 m 2 (–8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were –7.9 (–11.7 to –4.2) (week 26) and –4.7 (–9.1 to –0.3) (week 52); week-26-to-52 change was +3.0 (–1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan ( n =118) showed proteinuria reduction (geometric mean [95% CI] −63.0% [−69.9 to −54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [−3.8 to 4.0] mL/min/1.73 m 2 ). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. Conclusions: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
- 10 June 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (7) , 1123-1125
Complement Genetics in IgA Nephropathy
- 10 June 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (7) , 1123-1125
Complement Genetics in IgA Nephropathy
- Open Access
- 15 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3385-3402
Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons
C3 glomerulopathy (C3G) is a rare complement-mediated kidney disease. Pegcetacoplan [targeted complement 3 (C3)/C3b inhibitor] and iptacopan (factor B inhibitor) target the complement system and are approved for treatment of C3G in adults and adolescents (pegcetacoplan) or adults only (iptacopan). Currently, no head-to-head randomized controlled trials (RCTs) have assessed their relative efficacy. Indirect treatment comparisons (ITCs) were conducted using the Bucher (primary analysis-preserves randomization) and matching-adjusted indirect comparison (MAIC; supportive analyses-adjusts for trial differences) methodologies and data from two similarly designed, placebo-controlled, Phase III RCTs in C3G/primary immune-complex membranoproliferative glomerulonephritis [VALIANT (NCT05067127)] and C3G only [APPEAR-C3G (NCT04817618)]. Relative efficacy was assessed at 6 months (anchored Bucher and MAIC) and 12 months (anchored Bucher/MAIC plus unanchored MAIC). At 6 months, the Bucher analysis demonstrated pegcetacoplan was associated with a significantly greater reduction in urine protein-creatinine ratio (UPCR) relative to baseline versus iptacopan [mean difference -50.90% (95% confidence interval: - 67.34, - 26.18); p < 0.001]; also a significantly greater proportion of patients achieved UPCR reduction to < 1 g/g, UPCR reduction by ≥ 50%, and the composite renal endpoint [≥ 50% reduction in UPCR and ≤ 15% reduction in estimated glomerular filtration rate (eGFR)]. The between-trial difference in mean eGFR change from baseline was not statistically different between treatments. Results from the anchored MAIC were generally consistent with the Bucher analysis. At 12 months, pegcetacoplan was associated with a significantly greater reduction in UPCR from baseline versus iptacopan but not for eGFR. These ITCs indicate that, in patients with C3G, pegcetacoplan is associated with greater reductions in proteinuria levels, and more patients achieved the composite renal endpoint compared with iptacopan. The relative efficacy benefits for pegcetacoplan observed at 6 months were sustained at 12 months. These comparative effectiveness findings may help clinicians and payers better understand the utility of new therapies to treat patients with C3G.
- 15 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3385-3402
Open AccessPegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons
C3 glomerulopathy (C3G) is a rare complement-mediated kidney disease. Pegcetacoplan [targeted complement 3 (C3)/C3b inhibitor] and iptacopan (factor B inhibitor) target the complement system and are approved for treatment of C3G in adults and adolescents (pegcetacoplan) or adults only (iptacopan). Currently, no head-to-head randomized controlled trials (RCTs) have assessed their relative efficacy. Indirect treatment comparisons (ITCs) were conducted using the Bucher (primary analysis-preserves randomization) and matching-adjusted indirect comparison (MAIC; supportive analyses-adjusts for trial differences) methodologies and data from two similarly designed, placebo-controlled, Phase III RCTs in C3G/primary immune-complex membranoproliferative glomerulonephritis [VALIANT (NCT05067127)] and C3G only [APPEAR-C3G (NCT04817618)]. Relative efficacy was assessed at 6 months (anchored Bucher and MAIC) and 12 months (anchored Bucher/MAIC plus unanchored MAIC). At 6 months, the Bucher analysis demonstrated pegcetacoplan was associated with a significantly greater reduction in urine protein-creatinine ratio (UPCR) relative to baseline versus iptacopan [mean difference -50.90% (95% confidence interval: - 67.34, - 26.18); p < 0.001]; also a significantly greater proportion of patients achieved UPCR reduction to < 1 g/g, UPCR reduction by ≥ 50%, and the composite renal endpoint [≥ 50% reduction in UPCR and ≤ 15% reduction in estimated glomerular filtration rate (eGFR)]. The between-trial difference in mean eGFR change from baseline was not statistically different between treatments. Results from the anchored MAIC were generally consistent with the Bucher analysis. At 12 months, pegcetacoplan was associated with a significantly greater reduction in UPCR from baseline versus iptacopan but not for eGFR. These ITCs indicate that, in patients with C3G, pegcetacoplan is associated with greater reductions in proteinuria levels, and more patients achieved the composite renal endpoint compared with iptacopan. The relative efficacy benefits for pegcetacoplan observed at 6 months were sustained at 12 months. These comparative effectiveness findings may help clinicians and payers better understand the utility of new therapies to treat patients with C3G.
- Open Access
- 13 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 2102-2113
Impact of Disease Recurrence and Outcomes following Kidney Transplantation for GN
Key Points: GN is one of the main causes of kidney transplantation. In patients transplanted for GN, the risk of recurrence is approximately 16%. Recurrence significantly worsens the prognostic, tripling and doubling the risk of graft loss and acute rejection, respectively. Despite having more often received immunosuppression before transplantation, patients with GN are not at increased risk of post-transplantation cancers. Background: Patients who receive transplants after kidney failure due to GN (GN-KTx) constitute a significant portion of recipients and may face unique challenges post-transplantation, related to the risk of GN recurrence and a higher global burden of immunosuppression. Methods: We analyzed patient and graft outcomes, including the risk of graft loss in relation to recurrence in GN-KTx, compared with patients transplanted for other causes, using data from the prospective nationwide Swiss Transplant Cohort Study. Results: Among 2631 included patients, 701 were GN-KTx, with IgA nephropathy being the most common GN subtype. GN-KTx recipients were younger and more likely to receive living donor organs. During a mean follow-up period of 5.3 years (interquartile range, 2.3–8.2), the 5-year cumulative incidence of graft loss was similar across groups, with GN-KTx at 6%. Notably, GN-KTx had a similar incidence of acute rejection as other groups. Recurrence occurred in 16% of GN-KTx within a mean time of 1.7 years (interquartile range, 0.28–2). Patients with recurrence faced a three-fold higher risk of graft loss. Furthermore, disease recurrence was associated with a two-fold higher risk of acute rejection compared with nonrecurrent GN-KTx. Interestingly, regarding cancer risks, GN-KTx patients had the lowest incidence of skin cancer and no higher risk of nonskin cancers, despite greater exposure to immunosuppression compared with other kidney transplant recipients. Conclusions: These real-life setting contemporary multicenter data highlight the importance of post-transplant monitoring for GN recurrence, given the strong association with poor graft outcomes and higher rejection rates. This is important in the context of current development of targeted therapies for GN in native kidneys that could be transposed to transplanted kidneys.
- 13 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 2102-2113
Open AccessImpact of Disease Recurrence and Outcomes following Kidney Transplantation for GN
Key Points: GN is one of the main causes of kidney transplantation. In patients transplanted for GN, the risk of recurrence is approximately 16%. Recurrence significantly worsens the prognostic, tripling and doubling the risk of graft loss and acute rejection, respectively. Despite having more often received immunosuppression before transplantation, patients with GN are not at increased risk of post-transplantation cancers. Background: Patients who receive transplants after kidney failure due to GN (GN-KTx) constitute a significant portion of recipients and may face unique challenges post-transplantation, related to the risk of GN recurrence and a higher global burden of immunosuppression. Methods: We analyzed patient and graft outcomes, including the risk of graft loss in relation to recurrence in GN-KTx, compared with patients transplanted for other causes, using data from the prospective nationwide Swiss Transplant Cohort Study. Results: Among 2631 included patients, 701 were GN-KTx, with IgA nephropathy being the most common GN subtype. GN-KTx recipients were younger and more likely to receive living donor organs. During a mean follow-up period of 5.3 years (interquartile range, 2.3–8.2), the 5-year cumulative incidence of graft loss was similar across groups, with GN-KTx at 6%. Notably, GN-KTx had a similar incidence of acute rejection as other groups. Recurrence occurred in 16% of GN-KTx within a mean time of 1.7 years (interquartile range, 0.28–2). Patients with recurrence faced a three-fold higher risk of graft loss. Furthermore, disease recurrence was associated with a two-fold higher risk of acute rejection compared with nonrecurrent GN-KTx. Interestingly, regarding cancer risks, GN-KTx patients had the lowest incidence of skin cancer and no higher risk of nonskin cancers, despite greater exposure to immunosuppression compared with other kidney transplant recipients. Conclusions: These real-life setting contemporary multicenter data highlight the importance of post-transplant monitoring for GN recurrence, given the strong association with poor graft outcomes and higher rejection rates. This is important in the context of current development of targeted therapies for GN in native kidneys that could be transposed to transplanted kidneys.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1564-1566
Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?
An abstract is unavailable. This article is available as a PDF only.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1564-1566
Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?
An abstract is unavailable. This article is available as a PDF only.
- 5 September 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 322-339
Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post–C5 inhibitor era
- 5 September 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 322-339
Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post–C5 inhibitor era
- 18 July 2025
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 21 (10) , 671-686
Kidney health outcomes of hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy (HDPs), including pre-eclampsia (PE), are frequent, affecting 8-10% and 2-4% of all pregnancies, respectively. Among HDPs, PE is the best characterized and most frequently studied - it is a heterogeneous disease with different clinical phenotypes reflecting distinct underlying mechanisms that ultimately result in widespread endothelial dysfunction and systemic damage. HDP clinical remission is common after delivery, but the long-term health of women with a history of HDP is adversely affected compared with that of women with normotensive pregnancies. The relationship between HDP and kidney health is bidirectional: chronic kidney disease (CKD) increases the risk of HDP, and HDP raises the risk of future CKD. To what extent this increased risk of CKD after HDP is due to pre-existing CKD that is unmasked by pregnancy and/or whether HDP is a causal factor in CKD remains unclear. CKD is diagnosed in up to 20% of women after PE, and the lifetime risk of kidney failure after one episode of PE is 4-8 times higher than that of the general population, increasing further with PE recurrence. These risks are cross generational, as women born prematurely from pregnancies complicated by PE and fetal growth restriction can have low nephron mass, which would not only increase their lifetime risk of CKD but also their risk of developing PE in their own pregnancies.
- 18 July 2025
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 21 (10) , 671-686
Kidney health outcomes of hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy (HDPs), including pre-eclampsia (PE), are frequent, affecting 8-10% and 2-4% of all pregnancies, respectively. Among HDPs, PE is the best characterized and most frequently studied - it is a heterogeneous disease with different clinical phenotypes reflecting distinct underlying mechanisms that ultimately result in widespread endothelial dysfunction and systemic damage. HDP clinical remission is common after delivery, but the long-term health of women with a history of HDP is adversely affected compared with that of women with normotensive pregnancies. The relationship between HDP and kidney health is bidirectional: chronic kidney disease (CKD) increases the risk of HDP, and HDP raises the risk of future CKD. To what extent this increased risk of CKD after HDP is due to pre-existing CKD that is unmasked by pregnancy and/or whether HDP is a causal factor in CKD remains unclear. CKD is diagnosed in up to 20% of women after PE, and the lifetime risk of kidney failure after one episode of PE is 4-8 times higher than that of the general population, increasing further with PE recurrence. These risks are cross generational, as women born prematurely from pregnancies complicated by PE and fetal growth restriction can have low nephron mass, which would not only increase their lifetime risk of CKD but also their risk of developing PE in their own pregnancies.
- 16 October 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 150-152
Toward a Restrictive Use of Plasma Exchanges in Thrombotic Microangiopathies
An abstract is unavailable. This article is available as a PDF only.
- 16 October 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 150-152
Toward a Restrictive Use of Plasma Exchanges in Thrombotic Microangiopathies
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 15 October 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (1) , 75-86
Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis
- 15 October 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (1) , 75-86
Open AccessOutcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis
- Top Cited PapersOpen Access
- 10 October 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (1) , 87-98
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis
- 10 October 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (1) , 87-98
Top Cited PapersOpen AccessEfficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis